Testosterone replacement therapy (TRT) is one of the most prescribed interventions in men's health, yet it carries a significant and often underdiscussed side effect: suppression of the hypothalamic-pituitary-gonadal (HPG) axis. When exogenous testosterone is introduced, the hypothalamus detects elevated androgen levels and reduces GnRH pulsatility, leading to decreased LH and FSH production — and consequently, testicular atrophy and impaired spermatogenesis.
The HPG Axis Suppression Problem
The HPG axis operates on a negative feedback loop. Exogenous testosterone signals the hypothalamus to reduce GnRH output, which reduces pituitary LH and FSH secretion. Without LH stimulation, the Leydig cells in the testes cease endogenous testosterone production. Without FSH, Sertoli cells reduce sperm production. The result, over months to years of TRT, is testicular atrophy and potentially permanent fertility impairment.
Gonadorelin as the Solution
Gonadorelin is a synthetic analog of GnRH (gonadotropin-releasing hormone) — the same signal the hypothalamus uses to trigger LH and FSH release. By administering Gonadorelin in a pulsatile fashion (mimicking the natural 90-120 minute GnRH pulse), men on TRT can maintain LH and FSH signaling to the testes, preserving testicular volume, function, and fertility potential.
Clinical Protocol
The standard Gonadorelin protocol for men on TRT is 100mcg administered subcutaneously 2-3 times per week. This frequency approximates the natural pulsatile GnRH release pattern sufficiently to maintain testicular stimulation without causing receptor desensitization. Some practitioners use lower doses (50mcg) more frequently (daily) for a more physiological pattern.